01—Abstract
Summary
Summary of the 10-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported net sales of $3,268.8 milliona for 2024, essentially flat against $3,273.9 million in 2023, with organic net sales down 2% offset by a 2% contribution from acquisitions net of divestitures.
Diluted EPS attributable to IDEX was $6.64b, down 15% from $7.85, while adjusted diluted EPS was $7.89, down 4% from $8.22. Operating cash flow was $668.1 million, down 7%, and free cash flow was $603.0 million, down 4%. The Company's Health & Science Technologies segment saw the most pressure, with organic net sales down 10% amid cyclical softness in life sciences and semiconductor markets, while Fire & Safety/Diversified Products grew 4% in net sales.
The defining event of 2024 was the acquisition of Mott Corporation on September 5, 2024, for cash consideration of $986.2 millionc, net of cash acquired. The Company funded it with $211.9 million of cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from a $500 million 4.950% Senior Notes offering due 2029. Mott is described as the Company's largest acquisition to date.
Total borrowings rose to $1,971.3 milliond at December 31, 2024, from $1,333.3 million a year earlier, and the Company reported a 2.20 to 1 leverage ratio for covenant purposes against a 3.50 to 1 maximum. Looking ahead, management expects growth in HST from therapeutics, nutrition, satellite communications and datacenter-related energy demand, with semiconductor demand delayed until the second half of 2025.
In early 2025 the Company began organizational changes and expects approximately $21 million to $25 million of severance-related restructuring charges. The Company also repurchased 256,159 shares for $50.0 million in February 2025, leaving $539.7 million of authorization remaining at year-end 2024.
02—Key points
Key Highlights
- Net sales of $3,268.8 million were essentially flat versus $3,273.9 million in 2023; organic net sales declined 2%, offset by acquisitions net of divestitures.
- Diluted EPS attributable to IDEX was $6.64, down 15% from $7.85; adjusted diluted EPS was $7.89, down 4%.
- Acquisition of Mott Corporation closed September 5, 2024, for $986.2 million net of cash acquired, described as the Company's largest acquisition to date.
- Operating cash flow was $668.1 million (down 7%) and free cash flow was $603.0 million (down 4%), with free cash flow at 101% of adjusted net income.
- Health & Science Technologies organic net sales fell 10% on life sciences and semiconductor softness, while Fire & Safety/Diversified Products net sales rose 4%.
- Total borrowings increased to $1,971.3 million, with $500 million of 4.950% Senior Notes due 2029 issued in 2024; covenant leverage ratio was 2.20 to 1 versus a 3.50 to 1 maximum.
- Quarterly dividend increased 8% to $0.69 per share in 2024; $539.7 million remained under the share repurchase authorization at December 31, 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Idex kept $0.15.
- Revenue$3.27B100.0%
- Cost of revenue−$1.82B55.8%
- Gross profit$1.45B44.2%
- Operating costs−$768.0M23.5%
- Operating income$677.2M20.7%
- Interest, other & tax−$172.2M5.3%
- Net income$505.0M15.4%
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 20, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $3.27B$3.27B | −0.2% |
| Cost of Revenue | $1.82B$1.83B | −0.2% |
| Gross Profit | $1.45B$1.45B | −0.1% |
| R&D Expenses | $67.40M$68.40M | −1.5% |
| SG&A Expenses | $758.70M$703.50M | +7.8% |
| Operating Income | $677.20M$732.50M | −7.5% |
| Net Income | $505.00M$595.60M | −15.2% |
| EPS (Basic) | $6.66$7.87 | −15.4% |
| EPS (Diluted) | $6.64$7.85 | −15.4% |
| Shares Outstanding (Basic) | 75.70M75.60M | +0.1% |
| Shares Outstanding (Diluted) | 75.90M75.90M | 0.0% |
05—Questions
Frequently Asked Questions
What drove the decline in earnings per share in 2024?
Diluted EPS attributable to IDEX fell to $6.64 from $7.85, a 15% decline. The filing attributes the lower results to lower volumes from market softness, primarily in the Health & Science Technologies segment, along with higher employee-related costs, higher SG&A of $758.7 million versus $703.5 million, and a lower gain on sale of businesses. Gross margin was stable at 44.2%.
How was the Mott Corporation acquisition financed?
The $986.2 million net cash consideration was funded with $211.9 million of cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from the 4.950% Senior Notes due September 2029. Mott, which operates in the Scientific Fluidics & Optics reporting unit, recognized $483.6 million of goodwill and $412.8 million of intangible assets.
What is the outlook for 2025 according to management?
Management said most end markets are stable. HST is expected to grow from demand for new disease therapies and nutrition, global communication satellite expansion and datacenter energy consumption, while semiconductor demand is expected to remain delayed until the second half of 2025. FMT growth is expected mainly from water businesses, with pressure in energy and agriculture. FSDP growth is expected from fire and safety businesses.
Does the Company have sufficient liquidity and debt capacity?
At December 31, 2024, cash and cash equivalents were $620.8 million, with $462.7 million held outside the United States. Revolving Facility availability was $527.4 million of the $800.0 million capacity. The Company stated its current cash, operating cash flow and Revolving Facility availability are expected to be sufficient for its operating needs, capital expenditures, debt service, dividends and share repurchases. Current portion of long-term borrowings was $100.7 million.
What restructuring actions were announced after year-end 2024?
In the first quarter of 2025, the Company initiated organizational changes to connect scalable groups of businesses and shift toward horizontal frameworks, and eliminated layers in select areas. The Company expects these actions to result in approximately $21 million to $25 million of restructuring charges for severance related to employee reductions in 2025.
06—Continue